Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-05 | 2021-03-30 | 133385 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-19 | 2021-03-17 | 134439 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2021-02-26 | 2021-03-24 | 134820 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2021-04-05 | 2021-05-03 | 136805 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2021-04-23 | 2021-06-28 | 137962 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-06-04 | 2021-06-22 | 140420 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2021-06-25 | 2021-07-19 | 141537 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-02-22 | 2022-03-11 | 155362 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2022-09-01 | 2022-11-20 | 168421 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-09-16 | 2022-11-26 | 169513 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2022-10-21 | 2022-11-11 | 172342 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-12-16 | 2023-01-20 | 178742 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-02-23 | 2023-05-06 | 185459 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-03-02 | 2023-05-06 | 185942 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-06-16 | 2023-08-18 | 195063 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-08-04 | 2023-08-12 | 201171 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2023-09-07 | 2023-10-13 | 203849 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-09-28 | 2023-11-10 | 205489 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-09-28 | 2023-11-10 | 205498 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-02-09 | 2024-04-26 | 219171 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |